Perioperative Complications and Oncologic Outcomes of Nephrectomy Following Immune Checkpoint Inhibitor Therapy: A Multicenter Collaborative Study-Reference-Cited by-同舟云学术

Perioperative Complications and Oncologic Outcomes of Nephrectomy Following Immune Checkpoint Inhibitor Therapy: A Multicenter Collaborative Study

Published:2023-12 Issue:6 Volume:6 Page:604-610
ISSN:2588-9311
Container-title:European Urology Oncology
language:en
Short-container-title:European Urology Oncology

Author:

Yip Wesley,Ghoreifi Alireza,Gerald Thomas,Lee Randall,Howard Jeffrey,Asghar Aeen,Khanna Abhinav,Cai Jie,Aron Manju,Gill Inderbir,Thompson R. Houston,Uzzo Robert,Margulis Vitaly,Singla Nirmish,Djaladat Hooman

Publisher

Elsevier BV

Subject

Urology,Radiology, Nuclear Medicine and imaging,Oncology,Surgery

Reference30 articles.

1. Cancer statistics, 2022;Siegel;CA Cancer J Clin,2022

2. Epidemiologic and socioeconomic burden of metastatic renal cell carcinoma (mRCC): a literature review;Gupta;Cancer Treat Rev,2008

3. Surveillance after radical or partial nephrectomy for localized renal cell carcinoma and management of recurrent disease;Janzen;Urol Clin North Am,2003

4. Cytoreductive nephrectomy in patients with metastatic renal cancer: a combined analysis;Flanigan;J Urol,2004

5. Sunitinib alone or after nephrectomy in metastatic renal-cell carcinoma;Méjean;N Engl J Med,2018

Cited by 6 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Upfront versus deferred cytoreductive nephrectomy following targeted or immunotherapy: a population-based propensity score-matched analysis of perioperative complications;World Journal of Urology;2024-07-27

2. Perioperative organ dysfunction: a burden to be countered;Brazilian Journal of Anesthesiology (English Edition);2024-03

3. Beyond the knife: strategic patient selection for cytoreductive nephrectomy;Current Opinion in Urology;2024-01-18

4. Re: Wesley Yip, Alireza Ghoreifi, Thomas Gerald, et al. Perioperative Complications and Oncologic Outcomes of Nephrectomy Following Immune Checkpoint Inhibitor Therapy: A Multicenter Collaborative Study. Eur Urol Oncol. Eur Urol. Onc. 2023;604–610;European Urology Oncology;2023-12

5. Reply to Daniel D. Shapiro, Jose A. Karam, Viraj A. Master, et al.’s Letter to the Editor re: Wesley Yip, Alireza Ghoreifi, Thomas Gerald, et al. Perioperative Complications and Oncologic Outcomes of Nephrectomy Following Immune Checkpoint Inhibitor Therapy: A Multicenter Collaborative Study. Eur Urol Oncol. Eur Urol. Onc. 2023;604–610;European Urology Oncology;2023-12